BIGBEAR
PHARMACEUTICALS
Cabozantinib is an oral multi-targeted tyrosine kinase inhibitor with broad-spectrum anticancer activity.
AuthenticGuaranteeFast DeliveryPrivacy Cabozantinib is a broad-spectrum anticancer drug with multiple targets, inhibiting at least nine targets including MET, VEGFR1/2/3, ROS1, RET, AXL, NT···【Read More】
Update: 05 Mar,2026Source: Haiou HealthViews: 70
Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor developed by Exelixis in the United States. In November 2012, the FDA first a···【Read More】
Update: 05 Mar,2026Source: Haiou HealthViews: 71
Cabozantinib is a broad-spectrum, multi-target anti-tumor drug developed by Exelixis Biopharmaceuticals, Inc. While most anti-tumor drugs target 1-3 t···【Read More】
Update: 05 Mar,2026Source: Haiou HealthViews: 70
Cabozantinib (Cabometyx), first approved by the FDA in 2012, is a non-specific tyrosine kinase inhibitor. It exerts its anti-tumor effect by targeting···【Read More】
Update: 05 Mar,2026Source: Haiou HealthViews: 71
Cabozantinib (Cabometyx), first approved by the FDA in 2012, is a non-specific tyrosine kinase inhibitor. It exerts its anti-tumor effect by targeting···【Read More】
Update: 03 Mar,2026Source: Haiou HealthViews: 74
Cabozantinib is a broad-spectrum, multi-target anti-tumor drug developed by Exelixis Biopharmaceuticals, Inc. While most anti-tumor drugs target 1-3 t···【Read More】
Update: 28 Feb,2026Source: Haiou HealthViews: 70
Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor developed by Exelixis in the United States. In November 2012, the FDA first a···【Read More】
Update: 28 Feb,2026Source: Haiou HealthViews: 70
Cabozantinib is a broad-spectrum anticancer drug targeting multiple targets, inhibiting at least nine targets including MET, VEGFR1/2/3, ROS1, RET, AX···【Read More】
Update: 28 Feb,2026Source: Haiou HealthViews: 70
Copyright2024@ BIGBEAR All right reserved BIGBEAR
